Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

NCT01126749 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

92

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated as per sponsor's decision

Conditions

Bladder Cancer

Interventions

DRUG: Gemcitabine
DRUG: E7389
DRUG: Cisplatin

Sponsor

Eisai Inc.

Collaborators

[object Object]